Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Screening for pulmonary arterial hypertension in systemic sclerosis.

Weatherald J, Montani D, Jevnikar M, Jaïs X, Savale L, Humbert M.

Eur Respir Rev. 2019 Jul 31;28(153). pii: 190023. doi: 10.1183/16000617.0023-2019. Print 2019 Sep 30.

2.

Pulmonary Embolism: The Value of the Angiographic Diagnosis.

Leis B, Weatherald J, Basran R, De Villiers J.

Can J Cardiol. 2019 Jul;35(7):940.e1-940.e3. doi: 10.1016/j.cjca.2019.03.007. Epub 2019 Mar 19.

PMID:
31292095
3.

Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension.

Taniguchi Y, Jaïs X, Jevnikar M, Boucly A, Weatherald J, Brenot P, Planche O, Parent F, Savale L, Fadel E, Montani D, Humbert M, Sitbon O, Simonneau G.

J Heart Lung Transplant. 2019 Aug;38(8):833-842. doi: 10.1016/j.healun.2019.04.006. Epub 2019 Apr 27.

PMID:
31103383
4.

Pulmonary Hypertension and Exercise.

Vallerand JR, Weatherald J, Laveneziana P.

Clin Chest Med. 2019 Jun;40(2):459-469. doi: 10.1016/j.ccm.2019.02.003. Review.

PMID:
31078222
5.

Seeing the Forest for the (Arterial) Tree: Vascular Pruning and the Chronic Obstructive Pulmonary Disease Pulmonary Vascular Phenotype.

Weatherald J, Montani D, Humbert M.

Am J Respir Crit Care Med. 2019 Aug 15;200(4):406-408. doi: 10.1164/rccm.201901-0248ED. No abstract available.

PMID:
30908925
6.

A Prospective Evaluation of the Diagnostic Accuracy of the Physical Examination for Pulmonary Hypertension.

Braganza M, Shaw J, Solverson K, Vis D, Janovcik J, Varughese RA, Thakrar MV, Hirani N, Helmersen D, Weatherald J.

Chest. 2019 May;155(5):982-990. doi: 10.1016/j.chest.2019.01.035. Epub 2019 Feb 28.

PMID:
30826305
7.

Golden Ratio and the Proportionality Between Pulmonary Pressure Components in Pulmonary Arterial Hypertension.

Chemla D, Boulate D, Weatherald J, Lau EMT, Attal P, Savale L, Montani D, Fadel E, Mercier O, Sitbon O, Humbert M, Hervé P.

Chest. 2019 May;155(5):991-998. doi: 10.1016/j.chest.2018.12.006. Epub 2018 Dec 27.

PMID:
30594558
8.

Characterization of Right Ventricular Deformation in Pulmonary Arterial Hypertension Using Three-Dimensional Principal Strain Analysis.

Satriano A, Pournazari P, Hirani N, Helmersen D, Thakrar M, Weatherald J, White JA, Fine NM.

J Am Soc Echocardiogr. 2019 Mar;32(3):385-393. doi: 10.1016/j.echo.2018.10.001. Epub 2018 Dec 11.

PMID:
30552030
9.

Ion Channels in Pulmonary Hypertension: A Therapeutic Interest?

Lambert M, Capuano V, Olschewski A, Sabourin J, Nagaraj C, Girerd B, Weatherald J, Humbert M, Antigny F.

Int J Mol Sci. 2018 Oct 14;19(10). pii: E3162. doi: 10.3390/ijms19103162. Review.

10.

Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease.

Turpin M, Chantalat-Auger C, Parent F, Driss F, Lionnet F, Habibi A, Maître B, Huertas A, Jaïs X, Weatherald J, Montani D, Sitbon O, Simonneau G, Galactéros F, Humbert M, Bartolucci P, Savale L.

Eur Respir J. 2018 Oct 10;52(4). pii: 1800272. doi: 10.1183/13993003.00272-2018. Print 2018 Oct.

PMID:
30305330
11.

Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension.

Weatherald J, Boucly A, Launay D, Cottin V, Prévot G, Bourlier D, Dauphin C, Chaouat A, Savale L, Jaïs X, Jevnikar M, Traclet J, De Groote P, Simonneau G, Hachulla E, Mouthon L, Montani D, Humbert M, Sitbon O.

Eur Respir J. 2018 Oct 18;52(4). pii: 1800678. doi: 10.1183/13993003.00678-2018. Print 2018 Oct.

PMID:
30209196
12.

Risk stratification in pulmonary arterial hypertension.

Weatherald J, Boucly A, Sitbon O.

Curr Opin Pulm Med. 2018 Sep;24(5):407-415. doi: 10.1097/MCP.0000000000000510. Review.

PMID:
30004992
13.

Right heart catheterisation is still a fundamental part of the follow-up assessment of pulmonary arterial hypertension.

Humbert M, Weatherald J.

Eur Respir J. 2018 Jul 4;52(1). pii: 1800738. doi: 10.1183/13993003.00738-2018. Print 2018 Jul. No abstract available.

PMID:
29973355
14.

Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension.

Chemla D, Weatherald J, Lau EMT, Savale L, Boucly A, Attal P, Jaïs X, Parent F, Girerd B, Simonneau G, Montani D, Humbert M, Sitbon O, Hervé P.

Chest. 2018 Oct;154(4):882-892. doi: 10.1016/j.chest.2018.06.015. Epub 2018 Jun 27.

PMID:
29940163
15.

Factors predicting outcome after pulmonary endarterectomy.

Tromeur C, Jaïs X, Mercier O, Couturaud F, Montani D, Savale L, Jevnikar M, Weatherald J, Sitbon O, Parent F, Fabre D, Mussot S, Dartevelle P, Humbert M, Simonneau G, Fadel E.

PLoS One. 2018 Jun 21;13(6):e0198198. doi: 10.1371/journal.pone.0198198. eCollection 2018.

16.

Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension.

Weatherald J, Huertas A, Boucly A, Guignabert C, Taniguchi Y, Adir Y, Jevnikar M, Savale L, Jaïs X, Peng M, Simonneau G, Montani D, Humbert M, Sitbon O.

Chest. 2018 Oct;154(4):872-881. doi: 10.1016/j.chest.2018.05.006. Epub 2018 May 22.

PMID:
29800550
17.

Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis.

Launay D, Montani D, Hassoun PM, Cottin V, Le Pavec J, Clerson P, Sitbon O, Jaïs X, Savale L, Weatherald J, Sobanski V, Mathai SC, Shafiq M, Cordier JF, Hachulla E, Simonneau G, Humbert M.

PLoS One. 2018 May 15;13(5):e0197112. doi: 10.1371/journal.pone.0197112. eCollection 2018.

18.

Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension.

Taniguchi Y, Brenot P, Jais X, Garcia C, Weatherald J, Planche O, Fadel E, Humbert M, Simonneau G.

Chest. 2018 Sep;154(3):521-531. doi: 10.1016/j.chest.2018.03.059. Epub 2018 May 3.

PMID:
29730328
19.

Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era.

Savale L, Guignabert C, Weatherald J, Humbert M.

Eur Respir Rev. 2018 Apr 13;27(148). pii: 180004. doi: 10.1183/16000617.0004-2018. Print 2018 Jun 30. Review.

20.

Risk assessment in pulmonary arterial hypertension.

Boucly A, Weatherald J, Humbert M, Sitbon O.

Eur Respir J. 2018 Mar 29;51(3). pii: 1800279. doi: 10.1183/13993003.00279-2018. Print 2018 Mar. No abstract available.

PMID:
29599118
21.

Ventilatory response to exercise in cardiopulmonary disease: the role of chemosensitivity and dead space.

Weatherald J, Sattler C, Garcia G, Laveneziana P.

Eur Respir J. 2018 Feb 7;51(2). pii: 1700860. doi: 10.1183/13993003.00860-2017. Print 2018 Feb. Review.

22.

The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?

Weatherald J, Boucly A, Sahay S, Humbert M, Sitbon O.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):860-868. doi: 10.1164/rccm.201709-1840PP. No abstract available.

PMID:
29256625
23.

Acute decompensated pulmonary hypertension.

Savale L, Weatherald J, Jaïs X, Vuillard C, Boucly A, Jevnikar M, Montani D, Mercier O, Simonneau G, Fadel E, Sitbon O, Humbert M.

Eur Respir Rev. 2017 Nov 15;26(146). pii: 170092. doi: 10.1183/16000617.0092-2017. Print 2017 Dec 31. Review.

24.

Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.

Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M, Jaïs X, Taniguchi Y, O'Connell C, Parent F, Sattler C, Hervé P, Simonneau G, Montani D, Humbert M, Adir Y, Sitbon O.

Circulation. 2018 Feb 13;137(7):693-704. doi: 10.1161/CIRCULATIONAHA.117.029254. Epub 2017 Oct 25.

PMID:
29070502
25.

Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension.

Boucly A, Cottin V, Nunes H, Jaïs X, Tazi A, Prévôt G, Reynaud-Gaubert M, Dromer C, Viacroze C, Horeau-Langlard D, Pison C, Bergot E, Traclet J, Weatherald J, Simonneau G, Valeyre D, Montani D, Humbert M, Sitbon O, Savale L.

Eur Respir J. 2017 Oct 19;50(4). pii: 1700465. doi: 10.1183/13993003.00465-2017. Print 2017 Oct.

26.

Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Weatherald J, Savale L, Humbert M.

Curr Hypertens Rep. 2017 Oct 18;19(11):86. doi: 10.1007/s11906-017-0783-5. Review.

PMID:
29046979
27.

Are indexed values better for defining exercise pulmonary hypertension?

Weatherald J, Boucly A, Lau E, Godinas L, Savale L, Jaïs X, Montani D, Sitbon O, Simonneau G, Humbert M, Chemla D, Hervé P.

Eur Respir J. 2017 Sep 9;50(3). pii: 1700240. doi: 10.1183/13993003.00240-2017. Print 2017 Sep. No abstract available.

28.

Exertional dyspnoea in pulmonary arterial hypertension.

Dumitrescu D, Sitbon O, Weatherald J, Howard LS.

Eur Respir Rev. 2017 Sep 6;26(145). pii: 170039. doi: 10.1183/16000617.0039-2017. Print 2017 Sep 30. Review.

29.

Heritable pulmonary hypertension: from bench to bedside.

Girerd B, Weatherald J, Montani D, Humbert M.

Eur Respir Rev. 2017 Sep 6;26(145). pii: 170037. doi: 10.1183/16000617.0037-2017. Print 2017 Sep 30. Review.

30.

Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.

Boucly A, Weatherald J, Savale L, Jaïs X, Cottin V, Prevot G, Picard F, de Groote P, Jevnikar M, Bergot E, Chaouat A, Chabanne C, Bourdin A, Parent F, Montani D, Simonneau G, Humbert M, Sitbon O.

Eur Respir J. 2017 Aug 3;50(2). pii: 1700889. doi: 10.1183/13993003.00889-2017. Print 2017 Aug.

31.

Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.

Weatherald J, Chaumais MC, Savale L, Jaïs X, Seferian A, Canuet M, Bouvaist H, Magro P, Bergeron A, Guignabert C, Sitbon O, Simonneau G, Humbert M, Montani D.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700217. doi: 10.1183/13993003.00217-2017. Print 2017 Jul.

32.

Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension.

Godinas L, Sattler C, Lau EM, Jaïs X, Taniguchi Y, Jevnikar M, Weatherald J, Sitbon O, Savale L, Montani D, Simonneau G, Humbert M, Laveneziana P, Garcia G.

J Heart Lung Transplant. 2017 Nov;36(11):1234-1242. doi: 10.1016/j.healun.2017.05.024. Epub 2017 May 22.

PMID:
28666570
33.

Pulmonary arterial hypertension induced by tyrosine kinase inhibitors.

Weatherald J, Chaumais MC, Montani D.

Curr Opin Pulm Med. 2017 Sep;23(5):392-397. doi: 10.1097/MCP.0000000000000412. Review.

PMID:
28639957
34.

Validation of a risk assessment instrument for pulmonary arterial hypertension.

Weatherald J, Sitbon O, Humbert M.

Eur Heart J. 2018 Dec 14;39(47):4182-4185. doi: 10.1093/eurheartj/ehx301. No abstract available.

PMID:
28637288
35.

Mechanisms, measurement and management of exertional dyspnoea in asthma: Number 5 in the Series "Exertional dyspnoea" Edited by Pierantonio Laveneziana and Piergiuseppe Agostoni.

Weatherald J, Lougheed MD, Taillé C, Garcia G.

Eur Respir Rev. 2017 Jun 14;26(144). pii: 170015. doi: 10.1183/16000617.0015-2017. Print 2017 Jun 30. Review.

36.

Response to the article "Sorafenib as a potential strategy for refractory pulmonary arterial hypertension".

Weatherald J, Humbert M, Guignabert C, Montani D.

Pulm Pharmacol Ther. 2017 Aug;45:11-12. doi: 10.1016/j.pupt.2017.03.017. Epub 2017 Apr 4. No abstract available.

PMID:
28389260
37.

Cardiopulmonary Exercise Testing in Pulmonary Hypertension.

Weatherald J, Farina S, Bruno N, Laveneziana P.

Ann Am Thorac Soc. 2017 Jul;14(Supplement_1):S84-S92. doi: 10.1513/AnnalsATS.201610-788FR. Review.

PMID:
28375670
38.

Novelties in the Treatment of Pulmonary Hypertension.

Weatherald J, Taniguchi Y, Humbert M.

Arch Bronconeumol. 2017 May;53(5):235-236. doi: 10.1016/j.arbres.2017.01.016. Epub 2017 Mar 14. English, Spanish. No abstract available.

39.

Pulmonary arterial hypertension secondary to adult-onset Still's disease: Response to cyclosporine and sildenafil over 15 years of follow-up.

Weatherald J, Lategan J, Helmersen D.

Respir Med Case Rep. 2016 Jun 20;19:27-30. doi: 10.1016/j.rmcr.2016.06.007. eCollection 2016.

40.

Bronchoscopic resection of a central typical carcinoid tumour.

Weatherald J, Hirani N, Beaudoin EL, Chee A.

Can Respir J. 2015 Jan-Feb;22(1):16. No abstract available.

41.

Pseudocyanosis: drug-induced skin hyperpigmentation can mimic cyanosis.

Weatherald J, Marrie TJ.

Am J Med. 2008 May;121(5):385-6. doi: 10.1016/j.amjmed.2008.01.029. Review. No abstract available.

PMID:
18456031

Supplemental Content

Loading ...
Support Center